AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03459508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ophthalmological examination
Description: Detailed anterior segment examination using slit-lamp biomicroscopy for signs of anterior uveitis, and detailed fundus examination using slit-lamp fundus biomicroscopy with + 90 diopter lens searching for signs of vasculitis and posterior uveitis.
Study NCT00878579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDS System
Description: Percutaneous Dynamic Stabilization System
Study NCT00878579 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fusion
Description: Transforaminal Interbody Fusion (TLIF) with Autograft and Pedicle Screws
Study NCT01528280 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination against hepatitis A
Description: Vaccination against hepatitis A (2 doses) into the deltoid muscle of the nondominant arm twice, i.e., at 0 and 6 months.
Study NCT01528280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: No Intervention
Study NCT03615820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niosomal PPE oromucoadhesive film
Description: Niosomal PPE oromucoadhesive film in which Propolis entrapped in niosomal vesicles and incorporated in oromucoadhesive film
Study NCT03615820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niosomal PPE oromucoadhesive film
Description: Niosomal PPE oromucoadhesive film in which Propolis entrapped in niosomal vesicles and incorporated in oromucoadhesive film
Study NCT03615820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oromucoadhesive film
Description: Oromucoadhesive film without PPE control testing which represents Placebo group
Study NCT03615820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oromucoadhesive film
Description: Oromucoadhesive film without PPE control testing which represents Placebo group
Study NCT02860962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan Hydrobromide
Description: Dose as a single capsule preparation formulated by the Investigational Drug Service of MUSC specifically for the purposes of this trial.
Study NCT02860962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextromethorphan Hydrobromide
Description: Dose as a single capsule preparation formulated by the Investigational Drug Service of MUSC specifically for the purposes of this trial.
Study NCT04275453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDG
Description: FDG is a FDA approved radiotracer which each subject will have 3 positron emission tomography/computed tomography (PET/CT) scan performed.
Study NCT04275453 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Drink
Description: Subjects will undergo FDG PET/CT after 1 dose of ketone drink administration after 12 hours of fasting prior to FDG injection. The dosing of ketone drink administration (approximately 65 mL) will be weight based (714 mg/kg), which is crucial to replicating ketone levels between participants
Study NCT04275453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenetic Diet
Description: Subjects needs to be on Ketogenetic diet
Study NCT03038711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days
Study NCT03038711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-986166
Description: Specified dose on specified days
Study NCT05382429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OWHTO
Description: OWHTO Surgical procedure For the OWHTO Surgical procedure, only medial split biplanar osteotomy performed.
Study NCT05382429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CWHTO
Description: CWHTO Surgical procedure For the OWHTO Surgical procedure, only lateral closure osteotomy was performed.
Study NCT04089501 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stool collection
Description: Stool will be collected from subjects who have been diagnosed with IBD or whom small intestinal, colonic or ileocolonic and have signed consent for the control group. Stool will be self-collected or through routine colonoscopy procedure.
Study NCT04089501 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy collection
Description: 3 additional biopsies (for research purposes) will be taken from patients who undergo colonoscopy as per standard of care
Study NCT02660437 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation program
Description: Patients will attend a comprehensive 3-week PR program (12sessions/ 60min·day) including high intensive interval exercise equivalent to 100% of peak work rate (WRpeak) with 30sec work periods interspersed with 30sec rest periods for 30min and light resistance training (3muscle groups/ 4sets each/10repetitions; \~30min).
Study NCT02660437 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary Rehabilitation program
Description: Patients will attend a comprehensive 3-week PR program (12sessions/ 60min·day) including high intensive interval exercise equivalent to 100% of peak work rate (WRpeak) with 30sec work periods interspersed with 30sec rest periods for 30min and light resistance training (3muscle groups/ 4sets each/10repetitions; \~30min).
Study NCT02800369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZFN-603 and ZFN-758
Description: Each suppository contain 500 µg of ZFN-603 or ZFN-758
Study NCT02186158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Study NCT02186158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02362191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternating Current Stimulator
Description: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
Study NCT02815267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX-101, 4% minocycline foam
Description: FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
Study NCT02815267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle foam applied topically once daily for 12 weeks
Study NCT01717157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: DUROGESIC (8.4 mg fentanyl)
Description: One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.
Study NCT01717157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)
Description: One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
Study NCT01717157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)
Description: One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
Study NCT03995927 — intervention group
Intervention type: OTHER
Intervention: Quality of Life Questionnaire
Description: Participants will be asked to complete a set of short forms at first visit and post-treatment visits. If participant has a routine visit about 3 months after treatment, participant will be asked to complete a final form that is optional.
Study NCT01717157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)
Description: One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.
Study NCT01648153 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK1070806
Description: To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
Study NCT01648153 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: To compare the efficacy and biomarker changes between placebo and active groups
Study NCT01648153 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK1070806
Description: To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
Study NCT03435146 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 3HP plus DTG +2NRTIs
Description: * HIV treatment: DTG will be dosed as described above and will be given with daily TDF/FTC (Groups 1 and 2) or with TDF/3TC (Groups 3 and 4).~* LTBI treatment: 3HP will be given once-weekly for a total of 12 doses, with doses as follows:~Rifapentine: 900 mg; Isoniazid: 900 mg (Groups 1,2 and 4) Isoniazid at standard of care dosing (Group 3)
Study NCT01714167 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: intracerebral stem cell transplantation
Description: Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient
Study NCT02847442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily at bedtime, at least one hour before or after the last daily dose of L-dopa/DDCI.
Study NCT02847442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/dopa decarboxylase inhibitor
Description: OPC enhances the effects of L-dopa. Hence, it may be necessary to reduce the subject's L-dopa/DDCI dose within the first days or weeks of OPC treatment by extending the dosing intervals and/or reducing the amount of L-dopa/DDCI per dose
Study NCT00712647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta Carotene and Retinol
Description: Pilot participants (ppts):~Asbestos-Exposed--15 mg/day beta-carotene + 25,000 IU/day retinol Heavy Smokers--30 mg/day beta-carotene + 25,000 IU/day retinol~Vanguard \& Efficacy ppts:~Asbestos-exposed AND heavy smokers--30 mg/day beta-carotene + 25,000 IU/day retinol
Study NCT00712647 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebos, one each/day
Study NCT04154969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy including Vestibular rehabilitation
Description: vestibular exercise (VOR TX1)
Study NCT04154969 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional Physiotherapy
Description: conventional Physiotherapy
Study NCT04537988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: eCHANGE
Description: eCHANGE is an eHealth intervention aiming to support long-term weight maintenance after initial weight loss
Study NCT03792490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil
Description: Fasudil hydrochloride hydrate IV solution
Study NCT03792490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Fasudil hydrochloride hydrate, NaCl 0,9%
Study NCT01409005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and UFTE chemotherapy
Description: Gemcitabine : 800 mg/m2 mix with 150mL of normal saline (i.v.) over 30 min on Days 1, 8 and 15~UFTE : 200mg/m2 PO q 8 hr, Days 1\~21~Interval: every 4 weeks
Study NCT01545947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223, erlotinib
Description: Dose escalation: Combination doses start with 15 mg CC-223 and 100 mg erlotinib, or 15 mg CC-223 and 150 mg erlotonib, administered in 28-day cycles. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy
Study NCT01545947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223, oral azacitidine
Description: Dose escalation: Combination doses start with 15 mg CC-223 and 200 mg oral azacitidine, administered in 28-day cycle. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy
Study NCT01545947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223, oral azacitidine
Description: Dose escalation: Sequential dosing starts with 200 mg of oral azacitidine administered on Days 1 through 7 of each 28-day cycle, followed by daily dose level of 15 mg CC-223 on Days 8 through 28. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy
Study NCT00929253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suboxone
Description: Dosage Form: Oral Tablet; Dosage 6, 12, or 18 mg; Frequency; Daily; Duration 12 weeks
Study NCT00929253 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CRA
Description: Computer-delivered Community Reinforcement Approach
Study NCT00929253 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Therapist-delivered therapy
Study NCT00929253 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CM
Description: Contingency management (vouchers) for providing a drug negative urine sample.
Study NCT01717157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)
Description: One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.
Study NCT03013712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell immunotherapy
Description: This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen.
Study NCT02632370 — intervention group
Intervention type: DRUG
Intervention: Gliolan®
Description: single dose of oral 5-ALA (20mg/kg bodyweight) at 3 hours (range 2-5 hours) given preoperatively
Study NCT02632370 — intervention group
Intervention type: PROCEDURE
Intervention: Fluorescence-Guided Surgery
Description: performed utilizing blue light. At least 3-5 fluorescent tissue samples will be taken.
Study NCT06458777 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: poligraphy
Description: OSA diagnosis
Study NCT02210325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solithromycin
Study NCT02210325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Study NCT02210325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Study NCT01915550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT01915550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin Insulin Mixtard
Study NCT01400906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 100 micrograms Fluticasone propionate
Description: 100 micrograms micronized drug blended with lactose in dry powder inhalator
Study NCT01400906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 500 micrograms Fluticasone propionate
Description: 500 micrograms micronized drug blended with lactose in dry powder inhalator
Study NCT01400906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose powder
Description: lactose powder in dry powder device : placebo comparator
Study NCT01041274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: 40 mg by mouth daily for 12 months. Dosing will start at 20mg daily and may be increased after a minimum of one week to the target dose of 40 mg daily. Dose decreases will be made in the presence of side effects. Allowed dose range will be 10 mg daily to 40 mg daily.
Study NCT01041274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth daily for 12 months.
Study NCT01041274 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: 16 sessions of weekly, individual psychoeducation and relapse prevention planning followed by 8 monthly sessions
Study NCT01041274 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participants who exhibit symptoms of moderate suicidality at any point during the trial will be treated with 12 sessions of CBT, either once or twice weekly based on clinical judgment. Participants who continue to exceed suicidality criteria after 4 weeks of CBT will be dropped from double-blind treatment and may be prescribed openly an SSRI
Study NCT01041274 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: 3 1-hour sessions of fMRI brain scanning, assessed at baseline, and weeks 24 and 52
Study NCT02065518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: Participants will train at 15-20% of maximal voluntary contraction (MVC) during weeks 1-3, 21-30% of MVC during weeks 3-6 and 31-40% of MVC during weeks 6-9, 41-50% of MVC during weeks 9-12, then sustain 50% of MVC during weeks 12-18. Incremental increases will be made at the 3, 6, 9, and 12-week clinic visits.
Study NCT02065518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Walking
Description: Strength Walking participants will maintain a daily training log. Pedometer readings will form the basis for setting activity goals. Initial step goals will be 10% above the average 3-day pedometer step count taken at baseline, with a 10% increase every other week, and then a gradual increase when 30% above the baseline step count has been achieved. At week 7, participants will be given a weighted vest to begin the strengthening component. Participants will be instructed to wear the vest during their 30-minute walk, 3 to 4 days a week. The beginning weight load for the vest will be calculated using 2% of baseline body weight and it will be increased by that same amount every week thereafter until the end of the 12 weeks.
Study NCT02065518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Rehabilitation Protocol
Description: All participants will receive the current standard of care at the 2 military sites (Walter Reed National Military Medical Center (WRNMMC) and Malcolm Grow Medical Clinics and Surgery Center (MGMCSC)) of the physical therapy rehabilitation protocol for knee injuries. This program includes treatment with a physical therapist at WRNMMC and MGMCSC physical therapy clinic.
Study NCT02065518 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitation Protocol
Description: All participants will receive the current standard of care at the 2 military sites (Walter Reed National Military Medical Center (WRNMMC) and Malcolm Grow Medical Clinics and Surgery Center (MGMCSC)) of the physical therapy rehabilitation protocol for knee injuries. This program includes treatment with a physical therapist at WRNMMC and MGMCSC physical therapy clinic.
Study NCT03453697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acute intermittent hypoxia
Description: Adjust the proportion of nitrogen and oxygen, through increasing the suction nitrogen concentration, the subject's blood oxygen saturation could decrease to 80%\~90% within 30 seconds and also lasts 30 seconds; then quickly reduce the concentration of nitrogen gas suction to make the subject's blood oxygen saturation gradually return to normal level (consistent with the air inhalation), and then continue breathing air about 60 seconds to enter the next round of hypoxic state.
Study NCT00203047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer Acetate
Description: 20mg glatiramer acetate (GA) administered by daily subcutaneous injections
Study NCT03701152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure therapy
Description: Negative pressure therapy at sub atmospheric level
Study NCT01681095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol HTK
Description: After cross-clamping of the aorta approximately 1-2 L of Custodiol-HTK was infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml were administered as needed. The cardioplegic solution was delivered at a temperature of 4°C - 10°C.
Study NCT01681095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cold Blood Cardioplegia
Description: After cross-clamping the aorta, at least 1000 mL of a 4:1 mixture of cold blood: cold crystalloid was administered at a pressure of 300 mmHg or less via a twin roller pump. Every 20 minutes an additional > 200 mL was administered in an antegrade/retrograde fashion throughout the remainder of the case. The cardioplegic solution was delivered at a temperature of 4°C - 8°C.
Study NCT00203047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate
Description: 20mg glatiramer acetate (GA) administered by daily subcutaneous injections
Study NCT00203047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for prednisone given daily
Study NCT00203047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 1250 mg taken daily
Study NCT02497495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion cold water
Description: immersion cold water at different temperatures and exposure times
Study NCT00548743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening and follow up
Description: Two stage screening with EPDS and PHQ-9, treatment for depression at physician's discretion and follow up phone calls and visits